Mankind Pharma (MANKIND) — Announcement

📢 Key Event
Mankind Pharma enters exclusive in-licensing agreement for insulin degludec and combination therapy in India

💡 Investor Takeaway
This deal expands Mankind Pharma's diabetes portfolio and signals strategic growth in chronic disease treatments.

Mankind Pharma announced an exclusive in-licensing agreement with Chongqing Chenan Biopharmaceutical for insulin degludec and insulin degludec + aspart combination in India, expanding its diabetes portfolio and reinforcing its chronic disease strategy. The partnership strengthens its position in the injectable diabetes segment and leverages global innovation through Chinese biopharmaceutical assets.

📄 View Original Announcement (PDF)

📊 Stock Analysis — MANKIND ✨ Ask AI About This

About Mankind Pharma Limited (MANKIND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹97,467.05 Cr P/E: 47.7 ROE: 12.7% ROCE: 13.9% Div Yield: 0.04%

View full MANKIND stock details →

📡 Get AI alerts when MANKIND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MANKIND — Free

💡 Ask AI about this filing

"How will this partnership affect Mankind Pharma's revenue growth?" "What is the expected timeline for product launch in India?" "How does this deal compare to similar partnerships in the diabetes market?"

Ask AI Free →

📊 More MANKIND filings

See all MANKIND filings →

🔥 Also filed on 20 August 2026

JSLL Jeena Sikho Lifecare Limited Financial Results ANURAS Anupam Rasayan India Limited Financial Results NIRAJ Niraj Cement Structurals Limited Announcement PNBHOUSING PNB Housing Finance Limited Corporate Action KRONOX Kronox Lab Sciences Limited Announcement SUPRAJIT Suprajit Engineering Limited Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MANKIND files new disclosures

Track MANKIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MANKIND — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd